- Home
- ESAB vs QGEN Comparison
ESAB vs QGEN Comparison
Compare ESAB & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ESAB
- QGEN
- Stock Information
- Founded
- ESAB 1904
- QGEN 1986
- Country
- ESAB United States
- QGEN Netherlands
- Employees
- ESAB N/A
- QGEN N/A
- Industry
- ESAB Office Equipment/Supplies/Services
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ESAB Industrials
- QGEN Health Care
- Exchange
- ESAB Nasdaq
- QGEN Nasdaq
- Market Cap
- ESAB 7.8B
- QGEN 9.1B
- IPO Year
- ESAB N/A
- QGEN 1996
- Fundamental
- Price
- ESAB $124.54
- QGEN $48.18
- Analyst Decision
- ESAB Buy
- QGEN Buy
- Analyst Count
- ESAB 8
- QGEN 9
- Target Price
- ESAB $136.50
- QGEN $50.79
- AVG Volume (30 Days)
- ESAB 302.6K
- QGEN 1.3M
- Earning Date
- ESAB 08-01-2025
- QGEN 07-30-2025
- Dividend Yield
- ESAB 0.32%
- QGEN 3.13%
- EPS Growth
- ESAB 16.34
- QGEN N/A
- EPS
- ESAB 4.43
- QGEN 0.42
- Revenue
- ESAB $2,729,197,000.00
- QGEN $2,002,874,000.00
- Revenue This Year
- ESAB N/A
- QGEN $6.36
- Revenue Next Year
- ESAB $5.55
- QGEN $6.18
- P/E Ratio
- ESAB $28.33
- QGEN $114.29
- Revenue Growth
- ESAB N/A
- QGEN 3.31
- 52 Week Low
- ESAB $88.54
- QGEN $37.63
- 52 Week High
- ESAB $135.97
- QGEN $48.82
- Technical
- Relative Strength Index (RSI)
- ESAB 45.92
- QGEN 70.50
- Support Level
- ESAB $119.06
- QGEN $47.52
- Resistance Level
- ESAB $123.16
- QGEN $48.36
- Average True Range (ATR)
- ESAB 2.70
- QGEN 0.72
- MACD
- ESAB -0.14
- QGEN -0.00
- Stochastic Oscillator
- ESAB 48.96
- QGEN 77.53
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.7 billion in revenue in 2024.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).